Change in APOC3 level in response to treatment with APOC3 antisense oligonucleotide ISIS 304801 Phase 2, randomised, double-blind, placebo-controlled study.

Slides:

Advertisements

Similar presentations

Desmopressin: PRN Treatment in OAB Prospective, randomised, multi-centre, multinational, double-blind, placebo controlled observational study Prospective,

Advertisements

Hepatitis web study Hepatitis web study Sofosbuvir in Genotype 2 or 3 FUSION Trial Phase 3 *Note: Published in NEJM in tandem with POSITRON Trial (GT 2,3.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

Phase Difference = Phase Difference = 0.05.

Switch NNRTI to NNRTI  Switch EFV to ETR –CNS toxicity study –Patient’s preference study.

 decimals/cc-7th-fracs-to-decimals/v/converting-fractions-to-decimals-example.

CATIE STUDY Clinical Antipsychotic Trials of Intervention Effectiveness Effectiveness of Antipsychotic Drugs in patients with Chronic Schizophrenia – Lieberman.

Copyright © 2003 American Medical Association. All rights reserved.

Figure 2. Effect of Siberian and Panax ginseng respectively on postprandial glucose level before and after three months of intake in patients with type.

Volume 357, Issue 9273, Pages (June 2001)

Study Trial design No. of patients Randomisation Outcomes assessed

Study Trial design No. of patients Randomisation Outcomes assessed

Study Trial design No. of patients Randomisation Outcomes assessed

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

LEADER trial: Primary Outcome

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Etravirine in Treatment Experienced DUET-1 (TMC125-C206)

Placebo Metformin ***p < vs placebo

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

Filming: 15th of Febuary 2016, London, UK

James H. Liu, MD The American Journal of Medicine

Boceprevir in Treatment Naive SPRINT-2

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Placebo group 5-mg rimonabant group p 20-mg rimonabant group

A Novel Treatment of Premature Ejaculation

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Why double blind, controlled randomized trials?

Mean ADHD-RS-IV Scores at End Point

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.

Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results.

Sudhop T. et al. J Lipid Res 2009 Apr 20 [Epub ahead of print]

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial by Ersi Voskaridou,

Methods distribution among the three EQAs

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

Study design (A) and subject disposition (B).

Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial Dr.

Trial profile Luc F Van Gaal, Lancet 2005;365:1389.

Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial by Marc Russo, Mark Bloch, Fred de Looze, Christopher Morris, and.

Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Experimental Design Statistics.

Telaprevir in Treatment Experienced GT-1 PROVE3

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Cumulative survival without events during the first 42 days of treatment with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril (n=351)

Fig. 2. Soluble sugar and organic acid levels with different K fertilization during fruit development. Soluble sugar and organic acid levels with different.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Study schemas. Study schemas. Upper panel: single-ascending dose study. Subjects with mild, stable systemic lupus erythematosus (SLE) were randomised to.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

Effect of empagliflozin on efficacy parameters at week 18.

Subject disposition through week 156 of treatment

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Spasticity as measured by mean combined scores on the modified Ashworth scale, before and after treatment, on each day of each phase of the trial. Spasticity.

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple.

(A) Short Health Scale (SHS) dimension scores (left) and Psychological General Well-Being Index (PGWBI) global scores (right) for the open-label phase.

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

Change in APOC3 level in response to treatment with APOC3 antisense oligonucleotide ISIS 304801 Phase 2, randomised, double-blind, placebo-controlled study Mean Percentage Change in APOC3 Level placebo ISIS 304801, 100 mg ISIS 304801, 200 mg ISIS 304801, 300 mg Treatment period Study Day Adapted from: Gaudet et al., NEJM 2015

Change in triglyceride level in response to treatment with APOC3 antisense oligonucleotide ISIS 304801 Phase 2, randomised, double-blind, placebo-controlled study Mean Percentage Change in Triglyceride Level Treatment period placebo ISIS 304801, 100 mg ISIS 304801, 200 mg ISIS 304801, 300 mg Study Day Adapted from: Gaudet et al., NEJM 2015